Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma

Virchows Archiv

Volumn 463, Issue 4, 2013, Pages 553-562

  Fushimi, Fumiyoshi ^a   Taguchi, Kenichi ^b   Izumi, Hiroto ^c   Kohno, Kimitoshi ^c   Kuwano, Michihiko ^d   Ono, Mayumi ^d   Nakashima, Yutaka ^e   Takesue, Tetsuro ^e   Naito, Seiji ^a   Oda, Yoshinao ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

^e FUKUOKA RED CROSS HOSPITAL   (Japan)

Author keywords

Acquired cystic disease of kidney; Oxidative stress; Peroxiredoxin; Renal cell carcinoma; Y box binding protein 1

Indexed keywords

PEROXIREDOXIN; PEROXIREDOXIN 1; PEROXIREDOXIN 3; PEROXIREDOXIN 4; PEROXIREDOXIN 5; PEROXIREDOXIN 6; THIOREDOXIN; Y BOX BINDING PROTEIN 1;

ADULT; AGED; ANTIOXIDANT ACTIVITY; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIALYSIS; DISEASE COURSE; EPITHELIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KIDNEY CARCINOMA; KIDNEY CYST; MALE; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIREDOXINS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THIOREDOXINS; Y-BOX-BINDING PROTEIN 1;

EID: 84885587301     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-013-1460-y     Document Type: Article

References (31)

1. Del Vecchio L, Locatelli F, Carini M (2011) What we know about oxidative stress in patients with chronic kidney disease on dialysis - clinical effects, potential treatment, and prevention. Semin Dial 24:56-64
2. Kuntz E, Yusenko MV, Nagy A, Kovacs G (2010) Oligoarray comparative genomic hybridization of renal cell tumors that developed in patients with acquired cystic renal disease. Hum Pathol 41:1345-1349
3. Hori Y, Oda Y, Kiyoshima K et al (2007) Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis. J Pathol 212:218-26
4. Morgan MJ, Liu ZG (2011) Crosstalk of reactive oxygen species and NF-κB signaling. Cell Res 21:103-15
5. Cossu-Rocca P, Eble JN, Zhang S, Martignoni G, Brunelli M, Cheng L (2006) Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol 19:780-7
6. Cheuk W, Lo ES, Chan AK, Chan JK (2002) Atypical epithelial proliferations in acquired renal cystic disease harbor cytogenetic aberrations. Hum Pathol 33:761-5
7. Hofmann B, Hecht HJ, Flohe L (2002) Peroxiredoxins. Biol Chem 383:347-64
8. Arnér ES, Holmgren A (2000) Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 267:6102-9
9. Avila PC, Kropotov AV, Krutilina R, Krasnodembskay A, Tomilin NV, Serikov VB (2008) Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung 186:103-114
10. Cha MK, Suh KH, Kim IH (2009) Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res 28:93-104
11. Burke-Gaffney A, Callister ME, Nakamura H (2005) Thioredoxin: friend or foe in human disease? Trends Pharmacol Sci 26:398-404
12. Chen MF, Lee KD, Yeh CH et al (2010) Role of peroxiredoxin I in rectal cancer and related to p53 status. Int J Radiat Oncol Biol Phys 78:868-878
13. Wei Q, Jiang H, Xiao Z et al (2011) Sulfiredoxin-peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling. Proc Natl Acad Sci U S A 108:7004-9
14. Cohen SB, Ma W, Valova VA et al (2010) Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing. Oncogene 29:403-10
15. Hayakawa H, Uchiumi T, Fukuda T et al (2002) Binding capacity of human YB-1 protein for RNA containing 8-oxoguanine. Biochemistry 41:12739-44
16. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (eds) (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. Lyon, IARC
17. Shiota M, Izumi H, Miyamoto N et al (2008) Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high-mobility group protein B1. Cancer Sci 99:1950-9
18. Ohga T, Koike K, Ono M et al (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56:4224-8
19. Yasunaga M, Ohishi Y, Oda Y et al (2009) Immunohistochemical characterization of mullerian mucinous borderline tumors: possible histogenetic link with serous borderline tumors and low-grade endometrioid tumors. Hum Pathol 40:965-74
20. Basaki Y, Hosoi F, Oda Y et al (2007) Akt-dependent nuclear localization of Y-box-binding protein 1 in acquisition of malignant characteristics by human ovarian cancer cells. Oncogene 26:2736-46
21. Yang XJ, Tan MH, Kim HL et al (2005) A molecular classification of papillary renal cell carcinoma. Cancer Res 65:5628-37
22. Yoshida M, Yao M, Ishikawa I et al (2002) Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney. Genes Chromosomes Cancer 35:359-364
23. Nouh MA, Kuroda N, Yamashita M et al (2010) Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 105:620-7
24. Oda Y, Kohashi K, Yamamoto H et al (2008) Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 99:726-32
25. Choyke PL (2000) Acquired cystic kidney disease. Eur Radiol 10:1716-1721
26. Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-63
27. Carducci MA, Piantadosi S, Pound CR et al (1999) Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma. Urology 53:44-9
28. Kropotov A, Gogvadze V, Shupliakov O et al (2006) Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res 312:2806-2815
29. Karihtala P, Mäntyniemi A, Kang SW, Kinnula VL, Soini Y (2003) Peroxiredoxins in breast carcinoma. Clin Cancer Res 9:3418-24
30. Zhang B, Wang Y, Su Y (2009) Peroxiredoxins, a novel target in cancer radiotherapy. Cancer Lett 286:154-60
31. Tickoo SK, dePeralta-Venturina MN, Harik LR et al (2006) Spectrum of epithelial neoplasm in end stage renal disease: an experience from 66 tumor bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141-153